At the news
? NEUTRALIMPACT 5/10 8-K filed Feb 27, 2026 at 06:04 ET
Larimar Therapeutics is conducting a follow-on public offering of 20 million shares at $5.00 per share, with underwriters exercising their full option to purchase an additional 3 million shares, resulting in expected net proceeds of approximately $107.6 million. The company plans to use the proceeds for general corporate purposes, including advancing its clinical programs and expanding operations.
- Larimar Therapeutics is offering 20 million shares of common stock at $5.00 per share
- Underwriters exercised their full option to purchase an additional 3 million shares
- Expected net proceeds after underwriting discounts and commissions are approximately $107.6 million
- J.P. Morgan Securities LLC and Guggenheim Securities, LLC are acting as joint bookrunning managers
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access